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Abstract
Peripheral immune tolerance requires a finely controlled balance between tolerance to self-antigens and protective
immunity against enteric and invading pathogens. Self-reactive T cells sometimes escape thymic clonal deletion,
and can subsequently provoke autoimmune diseases such as type 1 diabetes (T1D) unless they are controlled by a
network of tolerance mechanisms in the periphery, including CD4
+ regulatory T cells (Treg) cells. CD4
+ Treg cells
are characterized by the constitutive expression of the IL-2Ra chain (CD25) and preferentially express the forkhead
winged helix transcriptional regulator Foxp3. These cells have been shown to possess immunosuppressive proper-
ties towards various immune cell subsets and their defects are thought to contribute to many autoimmune disor-
ders. Strong evidence shows that IL-2 is one of the important stimulatory signals for the development, function
and fitness of Treg cells. The non-obese diabetic (NOD) mouse model, a prototypic model of spontaneous autoim-
munity, mimics many features of human T1 D. Using this model, the contribution of the IL-2-IL-2R pathway to the
development of T1 D and other autoimmune disorders has been extensively studied. In the past years, strong
genetic and molecular evidence has indicated an essential role for the IL-2/IL-2R pathway in autoimmune disor-
ders. Thus, the major role of IL-2 is to maintain immune tolerance by promoting Treg cell development, functional
fitness and stability. Here we first summarize the genetic and experimental evidence demonstrating a role for IL-2
in autoimmunity, mainly through the study of the NOD mouse model, and analyze the cellular and molecular
mechanisms of its action on Treg cells. We then move on to describe how this data can be translated to applica-
tions for human autoimmune diseases by using IL-2 as a therapeutic agent to restore Treg cell fitness, numbers
and functions.
Introduction
Peripheral immune tolerance requires a finely controlled
balance between maintaining tolerance to self-antigens
and mounting protective immunity against enteric and
invading pathogens [1]. Self-reactive T cells sometimes
escape thymic clonal deletion, and can subsequently pro-
voke autoimmune diseases such as type 1 diabetes (T1D)
unless they are controlled by a network of tolerance
mechanisms in the periphery, including CD4
+ regulatory
T cells (Treg) cells [2]. These cells constitute 1-10% of
thymic and peripheral CD4
+ T cells in humans and mice,
and arise during normal thymic lymphocyte develop-
ment. Treg cells are characterized by the constitutive
expression of the IL-2Ra chain (CD25) and preferentially
express Foxp3, a forkhead winged helix transcriptional
regulator, which is critical for their development and
function [3]. CD4
+ Treg cells have been shown to possess
immunosuppressive properties towards various immune
cell subsets, although the mechanism varies according to
the genetic background of the host, microflora and target
tissue. As such, Treg depletion, or alterations of the foxp3
gene, as seen in Scurfy mice or IPEX patients, results in a
loss of Treg cells, and catastrophic multi-organ autoim-
munity [4,5]. Hence Treg cell homeostasis and function
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and their defect leads to organ-specific autoimmune dis-
orders such as T1 D.
The non-obese diabetic (NOD) mice are a prototypic
model of human autoimmunity as they spontaneously
develop multi-organ autoimmune diseases including
T1D [6]. T1 D is a chronic autoimmune disease that
results in the destruction of the insulin-producing beta
(b) cells of pancreatic islets of Langerhans, resulting in
insulin deficiency and persistent hyperglycemia. Devel-
opment of diabetes in NOD mice comprises several
stages: a non-pathogenic peri-islet immune infiltration
appears by 3-4 weeks (checkpoint 1). Following a clini-
cally silent period, a progressive T cell-dependent
destruction of the b islet cells occurs around 12 weeks
of age (checkpoint 2) [7]. Coincident with the checkpoint
1 to 2 transition, a switch between regulatory and pro-
inflammatory cytokine production occurs: prior to b cell
death, a period of Th2-dominated (IL-4/IL-10), non-
destructive insulitis is observed, followed by a destruc-
tive phase during which inflammatory cytokines such as
IFNg,T N F - a and IL-17 are produced. This step-wise
progression, as well as cytokine switch, has led to the
conclusion that waning immunoregulatory mechanisms
were involved in T1 D pathogenesis [8-10]. Indeed, stu-
dies suggest that reduced CD4
+ Treg cell frequencies or
function represent a primary predisposing factor to T1
D. Transfer of CD25-depleted splenocytes into NOD.
scid hosts leads to a quicker onset of T1 D than total
splenocytes [11]. A disruption of foxp3, B7/CD28 or
CD40/CD40L pathways in NOD mice alters the thymic
development and peripheral homeostasis of Treg cells,
and leads to an accelerated T1 D onset compared to
W TN O Dm i c e[ 1 2 , 1 3 ] .T h u s ,T 1Do n s e t / p r o g r e s s i o n
m a yb et r i g g e r e db yar e d u c t i o ni nF o x p 3
+ Treg cell
numbers and/or functions.
Strong evidence shows that IL-2, as well as other com-
mon gamma chain (gc; also known as CD132) signaling,
are important stimulatory signals for the development,
function and fitness of nTreg cells. Its signaling cascade
is initiated by the binding of IL-2 to its trimeric IL-2
receptor (IL-2R) which consists of the a-chain (IL-2Ra;
also known as CD25), the b-chain (IL-2Rb;a l s ok n o w n
as CD122) and the gc chain. All three subunits contri-
bute towards IL-2 binding, but only IL-2Rg and the gc
are required for signal transduction. The IL-2Rb and the
gc are also components of other cytokine receptors,
expressed by many cell types and tissue, whereas the
IL-2Ra expression is mostly restricted to activated
T cells, and Treg cells [14].
In recent years, strong genetic and molecular evidence
has shown that the IL-2/IL-2R pathway promotes Treg
cells development and functional fitness, and functional
variations of this pathway can promote susceptibility to
autoimmunity. Here, we review these recent findings
and explore the role of the Treg/IL-2 axis in the patho-
physiology of organ-specific autoimmune disorders such
as T1 D the functional potential of IL-2 and its possible
implication as a therapeutic agent in the context of
autoimmunity.
Genetic evidence for a role of IL-2 in autoimmunity
The IL-2-IL-2R pathway plays an essential role in the
development of T1 D and other autoimmune disorders
in humans and mice. IL-2 is well-described to promote
activated T cell proliferation, survival and differentiation
[15]. However, mice deficient for IL-2, IL-2Ra (CD25) or
IL-2Rb (CD122) die prematurely from a severe, multi-
organ, autoimmune and lymphoproliferative disorder
[16]. Similarly, rare genetic disorders due to mutations of
the il2, cd25 or stat5a/b genes lead to autoimmune syn-
dromes [17-19], emphasizing the importance of IL-2 in
the maintenance of self-tolerance [16].
Il2 allelic variation (Idd3) and resistance to autoimmunity
in NOD mice
T1 D susceptibility is inherited through multiple genes,
with a strong predisposition for those affecting T cell
responses to g cells [7]. At present, genomic mapping
studies of congenic NOD mice have identified 20 insu-
lin-dependent regions (Idd) that influence either the
onset insulitis, progression to overt T1 D, or both [20].
No single gene is both necessary and sufficient for T1 D
susceptibility. Of particular interest is the Idd3 locus
which was mapped to a 0.15-cM interval on the proxi-
mal mouse chromosome 3 between the microsatellite
markers D3Nds55 and D3Nds40b [20-22]. Fine mapping
studies show that the Idd3 locus encompasses several
genes of potential immune relevance, notably: Il-2, testis
nuclear RNA-binding protein (Tenr), Il-21,C e n t r i n4
(Cetn4) and Fibroblast growth factor 2 (Fgf2)[ 2 0 ] ,
although the IL-2 gene is the strongest and primary can-
didate gene for protection in NOD mice congenic for
the C57BL/6 Idd3 locus [20,22]. NOD mice introgressed
with the protective Idd3 allele from C57BL/6 display a
reduced onset and severity of T1 D, as well as reduced
susceptibility to other organ-specific autoimmune disor-
ders, such as experimental autoimmune encephalomyeli-
tis (EAE) and autoimmune ovarian dysgenesis [23].
Yamanouchi et al. showed that expression of protective
Idd3 alleles in CD8
+ T cells results in a 2-fold increase
in IL-2 transcription and protein production compared
to susceptible alleles [22]. The protection conferred by
the Idd3 C57BL/6 allele can be explained by the pre-
sence of 46 SNPs upstream of the minimal promoter of
the IL-2 gene that can alter the transcriptional activity
of this gene compared to NOD mice [22]. Moreover,
polymorphisms in il2 exon 1 cause multiple amino acid
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differential glycosylation pattern [24]. As such, the pre-
sence of a proline rather than a serine at position 6 of
the mature IL-2 protein, is associated with an increased
glycosylation and prolongation of the IL-2 half life [24].
However, NOD.CZECH Idd3 mice, whose IL-2 glycosy-
lation pattern is identical to that of wild-type NOD
mice, is resistant to T1 D, suggesting that glycosylation
differences, on their own, do not account for T1 D pro-
tection in NOD.B6 Idd3 mice [22]. Candidate-gene
approaches have also demonstrated a role for the Idd3
locus in human celiac disease and RA [25], as well as in
T1D [26,27]. Interestingly, neither the Idd3 locus, nor
any of the candidate genes enclosed therein (il-2, il-21),
have been identified as correlating with T1 D in the
recent genome-wide association studies (GWAS).
cd25 genetic polymorphisms are associated with human
T1 D
Genetic evidence linking the IL-2/IL-2RA pathway to
the predisposition of human autoimmunity, and in parti-
cular T1 D, has also emerged in recent years. First, Vella
et al. observed that SNPs in the cd25 gene indeed corre-
late with T1 D in a large European cohort. However,
this quite large interval also encompasses other
immune-relevant genes such as IL15RA, and the authors
could not pin-point the causal variant with the locus
[28]. The genetic interval was significantly narrowed
down thanks to the power of GWAS performed on
large cohorts around the world. As such, two sets of
SNPs have been identified in the 5’ and 3’ vicinity of the
promoter of IL-2RA [29-31]. The molecular and func-
tional consequences of these SNPs remain to be charac-
terized, however they seemingly do not cause splicing
variations, nor do they directly affect the five known
promoter regulatory regions of CD25 [31]. Some
insights could come from the observation that levels of
the soluble form of CD25 (sIL-2-RA) are slightly lower
in the serum of patients carrying predisposing alleles
[31], although the functional relevance of sIL-2-RA is
ill-defined. Indeed, sIL-2RA seems to be able to partially
block signaling downstream of IL-2 in vitro,a l l - t h e -
while enhancing T cell activation and proliferation [32],
a finding reminiscent of the recent observation on the
impact of IL-2/anti-IL-2 mAb complexes (discussed
below).
As t u d yb yQ uet al. observed an allelic imbalance of
the CD25 SNP variants whereby the susceptibility haplo-
type correlates with lower CD25 mRNA in lymphoblas-
toid cell lines [33]. In accordance, it was simultaneously
shown that CD4
+ T cells of the memory subset display
higher surface expression levels of CD25 in patients har-
boring a predisposing allele [34]. CD25 SNPs have been
suggested to affect the onset and progression to T1 D.
Indeed, a study of late-onset T1 D in a Finnish cohort
suggested that the predisposing SNPs originally
described by Lowe et al. also correlate with the age of
onset, and do so as strongly as the HLA-DQ2/DQ8 pre-
disposing haplotype [35]. Furthermore, the predisposing
haplotype of CD25 SNPs described by Qu et al. [29]
was found to correlate with acute-onset diabetes, but
not slow-onset or fulminant, in a Japanese cohort [36].
Role of IL-2 in stabilizing Foxp3
+ Treg cells homeostasis
in T1 D progression
Defective Treg cell fitness and survival in target organ as a
trigger of autoimmunity
Several lines of evidence point to a critical role of the
IL-2/IL-2R pathway in Treg cell development, function
and homeostasis in human and murine autoimmunity.
First, we and others have asked whether a possible
quantitative or qualitative deficiency in Foxp3
+CD4
+
Treg cells contributes to the onset and establishment of
autoimmune diabetes in NOD mice [8]. We showed
that thymic and peripheral CD4
+CD25
+ T cells are fully
functional in vitro and in vivo in both normal NOD
mice and the BDC2.5 antigen-specific model of T1D [8].
Furthermore, Treg cells do not affect the priming or
expansion of antigen-specific diabetogenic T cells in
pancreatic lymph nodes, but regulate late events of dia-
betogenesis by localizing in the pancreas where they
suppress the accumulation and function of effector Th1
and Th17 cells [8]. Interestingly, the function of Treg
cells, while fully operative in neonatal mice, declines
progressively with age [8]. The proportion of Foxp3
+
Treg cells in secondary lymphoid tissues is similar in
the NOD mice relative to T1D-resistant C57BL/6 mice
While T1 D progression is not attributed to systemic
fluctuations in CD4
+Foxp3
+ Treg cell numbers, there is
a paradoxical increase of Treg cells in the pancLN at T1
D onset [8]. Interestingly, the transition from peri-insuli-
tis (checkpoint 1) stage to T1 D onset (checkpoint2) is
associated with a progressive loss of CD4
+Foxp3
+ Treg
cells in pancreas, but not in the pancLN, which in turn
perturbs the Treg/Teff cell balance and allows the trig-
gering of Teff cell pathogenicity in inflamed islets [8].
Moreover, intra-islet Treg cells expressed reduced
amounts of CD25 and Bcl-2 relative to Treg cells in the
pLN, suggesting that the Treg/Teff cell imbalance was
due a defect in intra-islet Treg survival [10]. Collectively,
these studies suggest that T1 D onset is associated with
a loss of Treg cells numbers or/and function [37-42].
Several findings suggest that IL-2/IL-2R signaling is
necessary for the peripheral maintenance and fitness of
Treg cells. In Fontenot et al., the analysis of Foxp3-GFP
reporter knock-in mice genetically deficient for IL-2 or
IL-2R (CD25) revealed that IL-2 signaling is not
required for the induction of Foxp3 expression in
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demonstrating that Treg cell development is indepen-
dent of IL-2, while this cytokine is essential for survival
of Treg cells [43]. Moreover, although IL-2
-/- or IL-2R
-/-
mice display reduced numbers of Treg cells in vivo,
their suppressive function in vitro remains unaffected
[44]. Nonetheless, gene expression analysis showed that
IL-2 signaling was required for the maintenance of the
expression of the genes involved in the regulation of cell
growth and metabolism [22]. Hence, IL-2 has a critical
role in the homeostasis and competitive fitness of Treg
cells [3]. Interestingly, the adoptive transfer of WT Treg
cells either in IL-2
-/- or IL-2R
-/- mice can only prevent
autoimmunity in IL-2R
-/-,a n dn o tI L - 2
-/-, mice [16,45].
These results indicate that the lack of Treg cells in
IL-2
-/- and IL-2R
-/- mice contributes to the autoimmune
phenotype and that IL-2 maintains self tolerance by
increasing the number of Treg cells present in the per-
ipheral organs [46].
Similarly, T cell-specific deletion of STAT5a/b leads to
reduced Treg cell numbers [47]. Antov et al.d e m o n -
strated that adoptive transfer of C57BL/6 background
WT mice CD4
+CD25
+ Treg cells into STAT5
-/-,m i c e
was sufficient to prevent the development of splenome-
galy and autoimmunity, demonstrating that disease
symptoms in STAT5 mice are due to defective Treg
cells [48]. Another player in the IL-2 signaling cascades
is the Jak3 kinase. Jak3
-/- mice display symptoms of
autoimmunity and accumulation of auto-reactive T cells
in the lymphoid organs [48]. It has been shown that the
frequency of CD25
+CD4
+ Treg cells in the spleen of
Jak3
-/- mice was similar to that in IL-2
-/- and IL-2b
-/-
mice, and was reduced compared to the C57BL/6 back-
ground WT mice [48]. Altogether, these findings indi-
cate that Jak3 and STAT5a/b signals are required to
maintain normal numbers of Treg cells in peripheral
lymphoid organs and maintain self-tolerance down-
stream of IL-2/IL-2R signaling. Overall, IL-2 may not be
absolutely required for the thymic generation of Treg
cells but is a critical contributor of peripheral tolerance
by maintaining a fit Treg cell pool.
IL-2 restores the Treg/Teff balance in T1 D
The importance of IL-2 in the maintenance of Treg cell
homeostasis and suppression in T1 D has been sug-
gested by IL-2 neutralization studies [49]. Administra-
tion of an IL-2-neutralizing antibody into neonatal NOD
mice precipitated T1 D development by selectively
depleting the Treg cell subset, reinforcing the impor-
tance of IL-2 in promoting Treg cell functions [49].
S i m i l a r l y ,ar e c e n ts t u d yb yT a n get al.s h o w e dt h a t
CD4
+ Teff from islets of NOD mice were selectively
impaired to produce IL-2, consistent with s report docu-
menting the appearance of TCR hyporesponsive T cells
coincident with the development of insulitis [10].
Conversely, low dose administration of IL-2 in pre-
diabetic NOD mice restored CD25 expression and survi-
val in intra-islet Treg cells, increase of the overall fre-
quency of Foxp3
+CD25
+ Treg cells in islets and led to
T 1Dp r e v e n t i o n[ 5 0 ] .O v e r a l l ,t h e s er e s u l t ss h o wt h a t
an IL-2 deficiency contributes to intra-islet Treg cell dys-
function and progressive loss of self-tolerance in the
islets.
As discussed above, the increased transcriptional activ-
ity of protective Idd3 alleles translates into higher levels
of IL-2 production by auto-reactive CD8
+ T cells in
response to antigenic stimulation and, controls the size
of the Treg cell pool in the pancreatic lymph nodes of
NOD mice [10,22] These results show that IL-2 gene
variation may affect the balance between islet-specific
auto-reactive T cells and Foxp3
+ Treg cells, and conse-
quently precipitate T1 D. In Sgouroudis et al., we asked
if Il2 allelic variation potentiates Foxp3
+ Treg cell-
mediated regulation of T1D [9]. NOD.Idd3
B6 mice show
a markedly reduced incidence and delayed T1 D onset
compared to control NOD mice. This resistance is asso-
ciated with significantly reduced insulitis scores and fre-
quencies of IFN-g,T N F - a and IL-17 secreting
autoreactive CD4
+ T cells, and correlates with increased
IL-2 gene expression and protein production in antigen-
activated CD4
+ Teff cells [9]. The Idd3
B6 allele favors the
suppressive functions of Treg cells in vitro,a n dt h i s
increased Treg cell function, in contrast to controls,
restrains the expansion and effector functions of CD4
+
Teff cells more efficiently in vivo [9]. Interestingly, T1 D
resistance in Idd3
B6 mice correlates with the ability of
protective Il2 allelic variants to promote the expansion
of Treg cells directly within islets undergoing autoim-
mune attack [9,51]. Thus, T1D-protective IL2 allelic var-
iants impinge the development of g-islet autoimmunity
by bolstering the IL-2 production of pathogenic CD4
+
Teff cells, and in turn, driving the functional homeosta-
sis of CD4
+Foxp3
+ Treg cells in the target organ.
Treg lineage commitment and stability of Foxp3
expression
IL-2 is important in instructing Treg lineage commit-
ment. Apart from thymic-derived Treg cells, induced
Treg cells can acquire Foxp3 expression following T cell
activation in the periphery, a process that is facilitated
by IL-2 [52]. For example, TGF-g1 induction of Foxp3-
expressing Treg cells in vitro is highly dependent on
IL-2. Recent evidence also points to the functional plas-
ticity of Foxp3
+ Treg cells in which Foxp3 expression
and suppressive activity can be modulated in pre-
committed Foxp3
+ Treg cells depending on the inflam-
matory milieu. This is evidenced by a recent study by
Zhou et al.w h i c hp o i n t so u tt h a tal o s so fF o x p 3
expression within Treg cells has been described as a
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autoimmunity [53]. The ensuing unstable Foxp3
+ Treg
cells acquire a pathogenic phenotype, as reflected by the
production of pathogenic cytokines such as IFN- g and
IL-17, and contribute to the onset of T1D [53]. These
results suggest that an IL-2 functional deficiency in the
target organ may disturb the positive feedback loop that
controls Foxp3 stability, such that Treg cells convert to
Teff cells with a high diabetic potential. Moreover,
Komatsu et al. noted that Foxp3
+ cells with low CD25
expression lose more Foxp3 expression and become
effector T cells, where cells with high CD25 expression
are more resistant to such a conversion [54]. These find-
ings have important implications for the role of Foxp3
in Treg cell lineage commitment, suggesting a role of
IL-2 as a key player in Treg cell plasticity and heteroge-
neity. These studies also shape our thinking as some
human trials have been initiated that use Treg cells-
based immunotherapy.
Molecular basis underlying IL-2 mediated Treg cell
homeostasis
Recent evidence shows that microRNAs (miRNA) can
play an important role in the regulation of immunologi-
cal responses by influencing Foxp3 stability [55-57]. As
such, it has been shown that when DICER, a molecule
critical to the function of miRNA, is deleted, Treg cells
down-regulate Foxp3 expression, adopt an effector-like
phenotype, and mice rapidly develop a fatal systemic
autoimmune disease resembling the Scurfy syndrome
[58]. More specifically, miRNA155 is preferentially
expressed in Foxp3
+ cells, and a miR155 deficiency
results in an increased suppressor of cytokine signaling
1 (SOCS1) activity in Treg cells, which has been pre-
viously described as a negative regulator of the IL-2 sig-
naling. Furthermore, miR155-deficient Treg cells display
a low proliferative capacity in response to limiting
amounts of IL-2, whereas high amounts of IL-2 lead to
normal levels of STAT5 phosphorylation [55]. Hence
miRNA155 is required for Treg cell fitness in contexts
of differential IL-2 levels in contexts of homeostasis and
inflammation. Therefore, the waning of Treg cells, and
ensuing breakdown in the self tolerance, could depend
on the in situ IL-2 environment. These data all together
suggest that Treg cell stability and their responsiveness
to the IL-2 can be controlled by different miRNA there-
fore opening new avenues for potential therapeutic tar-
gets for the prevention and treatment of autoimmune
disorders.
IL-2 may also directly impact the survival of Foxp3
+
Treg cells by promoting the expression of CD25 and
Bcl2, a critical anti-apoptotic gene in T cells. Indeed,
Tang et al. have shown that progression from peri-insu-
litis to destructive insulitis in the NOD mice correlates
with intra-islet Treg cells expressing decreased levels of
CD25 and Bcl2. These data suggest that Treg cells
decrease in number by apoptosis due to a deficiency of
IL-2 in inflammatory sites [10]. Hence, IL-2 may func-
tion as critical an anti-apoptotic factor for Treg cells.
Evidence of Treg deficiencies in human T1 D
It is unclear whether a quantitative or qualitative Treg
cells defect contributes to human T1 D pathogenesis.
Indeed, some studies claim a numerical defect [59],
others a functional one [38,60], some none at all [61,62].
Defining Treg cells in human is much more challenging
than in mouse due to the lack of stringency of FOXP3
expression as a marker of Treg cells. Indeed, in humans,
FOXP3 is expressed by activated Teff cells [63], and
forced or natural expression of FOXP3 does not always
correlate with a regulatory function [2,64](our unpub-
lished data).
The association between IL-2 and Treg cells in
humans has also presented with more challenges than in
murine work, due to the lack of reliable phenotypic
markers discriminating human Treg from Teff cell
populations. In vitro studies have shown the absolute
necessity of IL-2 for the maintenance of FOXP3 expres-
sion and maintenance of the suppressive phenotype in
Treg-enriched CD4
+CD25
+ cells [65,66]. Accordingly, it
was further shown that Treg-enriched CD4
+CD25
+ cells
isolated from diabetic subjects displayed a concomitant
defect in IL-2 signaling and a difficulty to maintain
FOXP3 expression levels even in the presence of IL-2
[67]. This study does not, however, address whether a
potential loss of suppressive function correlates with
FOXP3 loss. Interestingly, the lack of suppression of
auto-reactive T-cells from peripheral blood of subjects
after the clinical onset of T1 D is due an increased
apoptosis in Treg cells, possibly mediated by deprivation
of growth signals such as IL-2 [68]. Hence, IL-2 has a
potential critical role in the fitness and/or lineage main-
tenance of human Treg cells, which is likely one of the
major mechanisms by which the IL-2/IL-2-RA pathway
impacts T1 D resistance in humans.
Autoantigen-driven Treg cell defects in organ-specific
autoimmunity?
An important aspect in our understanding of the patho-
genesis of autoimmunity is that potential immune
defects may only be apparent when and if they affect
autoantigen-specific fractions within Teff or Treg cell
compartments. Indeed, the onset of organ-specific auto-
i m m u n ed i s o r d e r ss u c ha sT 1D ,M Sa n dR A ,c a nb e
interpreted in two ways: 1) a cell-autonomous, geneti-
cally-driven, defect exists in autoantigen-specific Treg
cells, in turn leaving the activities of autoantigen-specific
Teff unchecked in a given organ. The local inflamma-
tory micro-environment or the degree of functional
Treg ablation are contributing factors which may unveil
this Treg defect, and in turn, mark the transition to
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Treg cell pool remain unaffected but genetic variation
influences immune selection and/or activation of anti-
gen-specific, pathogenic T cells, leading to a breakdown
of self tolerance in a given organ. These two scenarios
are of course non mutually-exclusive in individual
subjects.
In the implications of such considerations lies the
relevance of studies examining defects on a global popu-
lation of Treg cells obtained from the peripheral blood,
as opposed to examining the defects solely in the anti-
gen-specific subset of T cells, and Treg cells in particu-
lar. Indeed, only islet-specific T cells can enter the
pancreas to contribute to diabetes [69]. Additionally, the
T cells found in the blood, whether it be in their reper-
toire, function and state of activation, may not accu-
rately reflect the status and behavior of their
counterparts localized in the target organ.
In this latter regard, there is experimental evidence that
the blood carries at least a fraction of those cells with
undeniable pathogenic potential. As such, it has been
shown that beta islet cell-specific CD8
+ T cells can be
found in the blood of mice, that constitute a predictive
marker of onset [70-72]. Furthermore, the number of
islet-specific CD4
+ T cells increases in the blood of pre-
diabetic mice in correlation with increased infiltration of
p a n c r e a s ,h o w e v e r ,t h e i rr e p e r t o i r e ,u n l i k eC D 8
+ cells,
was found to be more restricted in the islet than in the
blood [73]. The authors also point out that when taken
in blood, antigen-specific CD4
+ T cells are less patho-
genic, whereby when adoptively transferred, recipients do
not develop disease unless the cells were obtained from
islets [74]. Thus, caution is required when interpreting
functional data obtained from peripheral blood.
In humans, islet-specific T cells are found in the blood
of normal subjects, but are slightly more prevalent in T1
D patients or at-risk subjects [75,76]. Interestingly, only
in at risk and T1 D patients does this subset exhibit mar-
kers of prior activation, namely the memory marker
CD45RO [77,78]. Given the extremely low abundance of
T1 D autoantigen-specific cells in the blood, combined
with the very low frequency of Treg cells, it has not been
elucidated yet whether or not quantitative or qualitative
defects in T1 D auto-Ag specific Treg cells can be
detected in the blood. Thus, observations from the blood,
if not mimic, at least reflect events ongoing at the specific
site of inflammation. Whether or not those events that
are translated into the blood encompass autoantigen-
specific Treg cell defects remains to be determined.
Modulation of the IL-2/IL-2R pathway for therapeutic
purposes
Given the strong link between IL-2 and autoimmunity,
it seems appealing to consider the use of IL-2 as a
therapeutic tool for T1 D. However, this might prove
quite challenging, as IL-2 is first and foremost a T cell
growth factor, and as such, has strong proliferative
effects on all T cells, including pathogenic CD4
+ and
CD8
+ Teff cells. For the past decade, IL-2 has been used
in the treatment of several diseases where the immune
system necessitates strengthening of the activated T cell
pool. As such, IL-2 is a frequent therapy in the treat-
ment of solid tumors, mainly melanoma and renal can-
cer. In such cases, high doses of IL-2 are injected
frequently leading to tumour regression in only about
10% of patients, and devastating side effects. While Teff
cells were believed to be the primary target of treatment
in treated patients, a 4-fold increase in suppressive CD4
+CD25
+FOXP3
+ cells was described although immune
responses in patients for whom IL-2 treatment had
worked were not analyzed [79]. Hence the main hurdle
to human IL-2 immunotherapy for T1 D is to obtain an
efficient and timely targeting of activated Treg versus
Teff cells during distinct phases of T1 D progression.
Several studies report the use of several strategies to
modulate IL-2 signals and ultimately impact the Teff/
Treg balance in vivo:
Low dose IL-2 prophylaxis therapy
Treg cells differ from their Teff counterparts in their
IL-2 signaling pathways. Indeed, Treg cells are able to
form the highest affinity receptor complex for IL-2, due
to their constitutive expression of CD25, making them
especially sensitive to very low levels of IL-2, in a fash-
ion that seems to be relatively independent of the
IL-2Rg chain [80]. This supports the rationale of exam-
ining the potential of low-dose IL-2 as a “Treg-only
enhancing treatment”. Low-dose IL-2 has been used for
several years to facilitate hematopoietic stem cell trans-
plantation (HSCT). Studies in such patients indicate that
Treg cells do increase in response to the treatment, and
that this effect seems to be increased with prolonged
time of treatment [66]. Of note is the fact that this effect
correlates with a medically positive outcome, i.e. absence
of graft rejection and GVHD. Accordingly, a low-dose
IL-2 regimen diminishes the magnitude and frequency
of CTL responses to a peptide vaccine against mela-
noma [81]. These observations are consistent with a
recent report showing that administration of low-dose
IL-2 promoted Treg cell survival and protected mice
from developing diabetes in NOD mice [10].
Anti-IL-2 blockade in vivo
One explanation for the initially observed need for high
doses of IL-2 in the treatment of cancer might have ori-
ginated from the very short half-life of purified IL-2
after injection (3-5 min in mice) [82]. However, high-
dose IL-2 leads to a devastating syndrome resembling
septic shock. Hence, several avenues have been explored
in order to stabilize the molecule in vivo, allowing for
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such, fusion with a carrier protein such as gelatin, BSA
or even an irrelevant immunoglobulin chain have suc-
cessfully prolonged IL-2 half life and reduced the side
effects [82].
The undesired emergence of Treg cells has been
pointed out as a potential culprit for treatment failure in
cancer. Thus, focus has been put on modulating the affi-
nity of IL-2 for its receptor complexes. Indeed, if IL-2
could be made to have a greater affinity for IL-2Rg than
IL-2Ra, the preferential bias of Treg cells in receiving
IL-2 signaling would be cancelled out. As such, targeted
mutations of the IL-2/IL-2RA binding sites have shown
promising results [82].
More recently, a novel therapeutic tool has emerged
that enables both higher stability, and selective cellular
targeting of IL-2 in vivo. Indeed, binding of IL-2 to its
receptor complexes could also be modulated by cou-
pling IL-2 with different anti-IL-2 monoclonal antibo-
dies (mAb). By varying the clone of the mAb, IL-2 can
be targeted preferentially towards either CD25 or
CD122 [82,83]. These complexes, when “stimulating”,
show a therapeutic effect in vivo in mice [84]. However
their exact mechanism of action remains unclear.
Recently, it was shown that the effect of the stimulating
IL-2/anti-IL-2 mAb complex treatment is recapitulated
by a conjoint prolongation of IL-2 half-life and a block-
ade of CD25. Moreover, the effect of IL-2/anti-IL-2
mAb does not depend on FcRs [85].
Combination therapy with rapamycin
Another way of selectively targeting Treg cells could be
the use of pharmacological agents that selectively modu-
late biochemical pathways in Teff or Treg cells. Rapamy-
cin (Sirolimus) is a commonly used immunosuppressive
drug which targets the cytosolic protein FK-binding pro-
tein 12 (FKBP12) and downstream mTOR pathway, and
in turn inhibits IL-2 responsiveness in activated T cells
[86]. Investigations into its mechanism of action have
highlighted that Treg cells respond differently than Teff.
Indeed, upon rapamycin treatment, Treg cells upregulate
anti-apoptotic, and down-regulate pro-apoptotic mole-
cules [87,88], in turn altering the Teff/Treg balance.
Interestingly, the same anti-apoptotic molecules were
increased downstream of IL-2 signaling [88]. Moreover,
rapamycin treatment in humans seems not to affect the
phenotype of Treg cells in vivo,a n dl e a d st oa ni n c r e a s e
of their functionality [89]. These findings have prompted
research into the use of combining IL-2 and rapamycin
therapies. In NOD mice, IL-2 synergizes with the thera-
peutic effects of sirolimus on T1 D development, leading
to a reduction in disease incidence of about 80%. The
effect was further confirmed to improve islet graft survi-
val in diabetic mice [90], although the cellular mechan-
isms underlying this protection have yet to be examined.
In humans, exposing CD4
+ T cells to both IL-2 and rapa-
mycin in vitro leads to an increase in the cellular fre-
quency of FOXP3
+ T cells, originating from nTreg cells
and de novo induced Treg cells [91]. Clinical trials are
currently underway to assess the effects and benefits of
this double therapy.
Combination therapy with cellular infusion
The idea of cellular therapy has also been examined.
The major challenge in this case is the very low abun-
dance of Treg cells. The possibility of expanding and/or
differentiating Treg cells in vitro prior to re-infusing
them into patients is currently the focus of several clini-
cal trials. One major limitation to such therapy could be
the lack of stability if these “artificial” Treg cells. Indeed,
FOXP3
+ Treg cells have been shown to fluctuate in
their phenotype, function, and FOXP3 expression levels
upon introduction in various murine models. Subse-
quently, studies have highlighted the instability and het-
erogeneity of the Treg transcriptional signature. Hence,
the risk of loss of function of massively injected Treg
population, and their subsequent likely conversion into
pathogenic T cells, casts doubts over the future of Treg
immunotherapy. Interestingly, IL-2 has been shown to
play a major role in the stabilization of the FOXP3
+
Treg phenotype and function [53]. Hence, IL-2 therapy
could, in combination with Treg infusion, represent a
plausible alternative. Indeed, low dose IL-2 in addition
to donor CD4
+ T cell infusion has shown to significantly
improve medical outcome in HSCT by increasing Treg
expansion in vivo [92].
Alternatively, administration of selective demethylation
agents and histone protein deacetylases could be consid-
ered in order to enhance Treg cell stability, as it has
been shown that Foxp3 expression is modulated by
DNA methylation via CpG islands in its promoter [93].
Also, as suggested by Blazar et al., it could be possible
to use clinical-grade lentiviral vectors in order to redir-
ect polyclonal Treg cells to the specific targets, as well
as to prevent Treg cell conversion to the Teff cells [94].
Thus, Treg cells could be engineered to constantly
express Foxp3, so that the infused Treg cells keep
Foxp3 expression.
Antigen-specific immunotherapy
The efficiency of Treg-mediated immunotherapy could
be greatly enhanced by focusing on auto-antigen specific
Treg cells. While Treg cells can suppress antigen non-
specifically in vitro, these cells need to home to and sup-
press antigen-specific responses in the target organ in
order to mediate disease protection [69]. This would also
reduce potential adverse effects of systemic immunosup-
pression in treated individuals. However, the identifica-
tion and isolation of antigen-specific Treg cells, existing
at very low frequencies in blood, poses significant hurdles
for their use in cellular infusion protocols. A potentially
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endogenous antigen-specific Treg population. Expansion
and/or de novo induction of Treg cells of a given specifi-
city can theoretically be achieved by an antigen vaccina-
tion strategy. This has proven efficient in the NOD
mouse model, as well as in other murine models of T1D
[95-100]. The feasibility of translating these therapies to
humans remains to be assessed. One potential limitation
of the process is the identification of those antigens that
are the most relevant as targets, as the human auto-anti-
gen-specific T cell repertoire is diverse and the optimal
antigen target could vary between patients [95]. More-
over, the possibility of conversion of antigen-specific
Treg cells into Teff cells would pose an even greater dan-
ger in the context of antigen-specific Treg cell therapies.
A deeper understanding of the factors that modulate this
phenotypic and functional plasticity in Foxp3
+ Treg cells
will be needed in order to implement Treg-cell based
therapies in autoimmune disease.
Conclusion
In conclusion, T1 D progression is associated with a tem-
poral loss of CD4
+Foxp3
+ Treg cells in b-islets, which
perturbs the Treg/Teff cell balance and unleashes the anti-
islet immune responses. Moreover, IL-2 deficiency is an
important trigger to intra-islet Treg cell dysfunction and
progressive loss of self-tolerance in the islets. Currently
there is great interest in the use of various immunothera-
peutic agents including IL-2 modulatory strategies, to pre-
vent T1 D in genetically susceptible individuals and/or
cure the overt disease. The induction and maintenance of
long lasting tolerance to islet autoantigens remains a major
goal of T1 D research. CD4
+ Treg cells represent major
players in the control of T1 D and offer much hope for
effective antigen-specific immunoregulation in the immedi-
ate future. However, several critical issues arise when con-
sidering the treatment of autoimmune disorders like T1D:
- Genetic-based identification of immune defects and
biomarkers of disease progression
Studies documenting quantitative or qualitative defects in
CD4
+Foxp3
+ Treg cells as a contributor to human T1 D
a r ei n c o n c l u s i v ea tb e s t .T h ei n a b i l i t yt od e t e c ti m m u n e
dysregulation in human T1 D as unequivocally as in the
murine models could be attributed to the lack of specific
and stable markers of human FOXP3
+ Treg cells. Indeed,
the accurate immune monitoring of human Treg cell fre-
quency and function in various clinical settings is primor-
dial to our understanding of the fundamental role of
these cells in the pathophysiology of many human dis-
eases. Moreover, we have no reason to assume that the
primary immune dysfunction is identical among indivi-
duals. Indeed, the existence of the two rodent models of
the NOD mouse and the BB rat, which display distinct
immune dysfunction genotypes/phenotypes, clearly
demonstrates the existence of at least two distinct
mechanisms that can lead to loss of g-cell tolerance.
Based on the genetic diversity of the human population,
the primary dysfunction can thus be assumed to differ
between individual T1 D subjects. Additionally, assuming
that a primary Treg defect is important in human T1 D,
it can be expected that many healthy controls will have
the same defect but not get T1 D because of other
genetic or environmental contributors. Conversely, this
defect may not be an absolute requirement and may be
absent from many of the cases. A more refined approach,
based on genetic-based selection of clinically stratified T1
D subjects, may now be feasible, given the recent break-
throughs in the genetics of T1D [101]. Knowledge of how
known and novel T1 D loci affect Treg cell development
and function can be expected to lead to assessments of
immune function that provide meaningful information
for the individual being tested.
The detection of T1D-specific antibodies is currently
used for meaningful and reliable prediction of T1 D,
years before clinical onset, but likely reflects ongoing
autoimmune responses towards b-islets. Although still
under development, assays of immune responses, and in
particular antigen-specific T cell responses could
become an alternative screening tool. However assays
are urgently required to measure not only the number/
function in pro-inflammatory, diabetogenic cells, but
also the induction, expansion and function of islet-speci-
fic Treg cells. Reliable assays to detect a primary (i.e.
genetically determined and preceding the autoimmune
process) immune dysfunction exist in the rodent models
but not in humans. Hence the critical question remains
of whether biomarkers can be developed to detect the
primary, genetically-determined, immune dysfunction
that leads to T1 D rather than the consequences of
autoimmunity induced on a given genetic background
by environmental triggers.
- When could a treatment be initiated/applied universally
to all T1D-susceptible subjects?
T1 D develops progressively, over several years, and is only
diagnosed once most of the damage to the pancreas has
already been done. Insights into human pathogenesis are
scarce, but the NOD model displays a step-wise pathogen-
esis, whereby insulitis occurs long before islet-destruction.
This suggests the existence of several so-called check-
points, when distinct immunological events are at play. As
such, therapeutic intervention can be expected to have a
different impact, dependingo nw h a ts t a g et h ed i s e a s e
development is at. These pathogenesis phases, however,
are still ill-defined in humans. The genetic and physiologi-
cal hallmarks of disease risk and progression have pre-
viously been thoroughly reviewed [101].
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